Validity of a Novel Screen for Cognitive Impairment and Neuropsychiatric Symptoms in Cardiac Rehabilitation
Overview
Authors
Affiliations
Background: Currently, there is no composite screening tool that can efficiently and effectively assess prevalent yet under-recognized cognitive and neuropsychiatric comorbidities in patients with cardiovascular disease. We aimed to determine the validity and feasibility of a novel screen assessing cognitive impairment, anxiety, apathy and depression (CAAD screen) in those attending cardiac rehabilitation (CR).
Methods: All patients diagnosed with cardiovascular disease or cardiovascular risk factors entering CR were screened as part of clinical care. A subset of those patients agreed to complete validation assessments (n = 127). Screen results were compared to widely accepted standards for cognition, anxiety, apathy, and depression using a modified receiver operating characteristic (ROC) and area under the curve analysis.
Results: The screen was completed by 97% of participants in 10 min or less with an average completion time of approximately 5 min. Screening scores adjusted for age, sex and years of education had acceptable or excellent validity compared to widely accepted standard diagnoses: CAAD-Cog (AUC = 0.80); CAAD-Anx (AUC = 0.81); CAAD-Apathy (AUC = 0.79) and CAAD-Dep (AUC = 0.85).
Conclusions: The CAAD screen may be a valid and feasible tool for detecting cognitive impairment, anxiety, apathy and depression in CR settings.
Hendawy N, Salaheldin T, Abuelezz S J Neuroimmune Pharmacol. 2023; 18(1-2):195-207.
PMID: 36781714 PMC: 10485135. DOI: 10.1007/s11481-023-10060-3.
Chen J, Thiyagarajah M, Song J, Chen C, Herrmann N, Gallagher D Alzheimers Res Ther. 2022; 14(1):23.
PMID: 35123548 PMC: 8818133. DOI: 10.1186/s13195-022-00961-5.
Cognition and Exercise: GENERAL OVERVIEW AND IMPLICATIONS FOR CARDIAC REHABILITATION.
Gaalema D, Mahoney K, Ballon J J Cardiopulm Rehabil Prev. 2021; 41(6):400-406.
PMID: 34561368 PMC: 8563446. DOI: 10.1097/HCR.0000000000000644.
Copenhaver M, Sanborn V, Shrestha R, Mistler C, Sullivan M, Gunstad J Drug Alcohol Depend. 2021; 224:108726.
PMID: 33930640 PMC: 8180490. DOI: 10.1016/j.drugalcdep.2021.108726.